NCT05594875View on ClinicalTrials.gov

A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

April 24, 2024

Study Completion Date

April 24, 2024

Conditions
Advanced Solid Tumor
Interventions
DRUG

SHR-1921

Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles

Trial Locations (4)

2031

Scientia Clinical Research, Sydney

2109

Macquarie Hospital, Sydney

2170

Sydney South West Private Hospital, Sydney

4101

ICON Cancer Centre, Brisbane

All Listed Sponsors
lead

Atridia Pty Ltd.

INDUSTRY